From “10,000-Ton Bet” to “5,000-Ton Test”: Acore’s Polyetheramine Dilemma—Is This a Symptom of Industry Winter or the Prelude to Strategic Retreat?

When a listed company downgrades the scale and timeline of the same fundraising project twice within a year, it’s no longer a mere “prudent adjustment”—it’s a loud alarm bell. In December 2025, Wuxi Acore Science & Technology Co., Ltd. (“Acore”) announced yet again that it would halve its originally planned “20,000-ton polyetheramine (PEA) project” to just 10,000 tons, cut total investment from RMB 3.27 billion to RMB 2.47 billion (a 24.4% reduction), and push back the commissioning date by a full year to December 2026. This marks the second major revision to the project since its initial delay in 2024 due to safety reviews. On the surface, the company frames this as an “active optimization based on market supply-demand dynamics”; in reality, the announcement betrays deep pessimism about industry prospects, anxiety over capital efficiency, and a painful retreat from overambitious expansion.

Polyetheramine—a seemingly obscure chemical intermediate—is in fact a critical component in wind turbine blades, EV battery adhesives, epoxy flooring, and even shale gas fracturing fluids. Fueled by the “dual carbon” policy wave over the past few years, surging wind power installations and explosive EV growth turned PEA into a “goldentrack” (golden track) for investors. As one of the few domestic players mastering continuous-process synthesis technology, Acore naturally refused to miss this boom. In October 2024, it raised RMB 2.07 billion through a private placement, pledging all proceeds to the 20,000-ton expansion, aiming to seize the high-end market. Yet dreams were lush, reality was lean—today, capacity is halved, timelines stretched, and the once-grand “10,000-ton bet” has quietly devolved into a cautious “5,000-ton test.”

The “Dammed Lake” of Overcapacity: Collapsing Prices and Industry-Wide Bleeding

Acore’s公告 casually notes that “product prices have continued to decline, and overall industry profitability is under pressure.” But behind these eight understated words lies an unfolding sectoral collapse. According to third-party data, since 2024, domestic PEA prices (e.g., D230 grade) have plummeted from around RMB 38,000/ton at the start of the year to just RMB 23,000/ton by late 2025—a nearly 40% drop. Meanwhile, raw material costs (such as propylene oxide and acrylonitrile) have fluctuated but not fallen nearly as steeply, pushing industry-wide gross margins below 15%, with some new entrants already operating at a loss.

Why such a brutal price crash? The root cause is a massive mismatch between runaway capacity expansion and modest demand growth. Between 2022 and 2024, China approved over 150,000 tons of new PEA capacity, while global annual demand stands at only around 300,000 tons—and growing at a compound rate of just ~12%. Worse, this new capacity hit the market almost simultaneously: companies like Chenhua, Zhengda New Materials, and Yueyang Xingchang all launched 10,000-ton+ plants, creating a vicious cycle where “production means oversupply.”

Acore had hoped its technological edge—its energy-efficient, high-purity continuous process—would let it target premium segments and avoid price wars. But when industry utilization rates fall below 60%, even high-end customers start squeezing suppliers on cost. A wind blade manufacturer admitted bluntly: “Suppliers are lining up to offer samples—if you’re RMB 500/ton cheaper, we’ll switch.” In this environment, forcing through the original 20,000-ton plan would be economic suicide.

Safety Reviews Were Just the Spark—The Real “Time Bomb” Was Blind Expansion

The company repeatedly cites the 2024 safety review—which required redesign of tank farms and loading zones—as the reason for delays, implying external, uncontrollable forces derailed the schedule. But a closer look suggests this is more of a cover for inadequate upfront project planning. PEA is a hazardous chemical; its production involves high-temperature, high-pressure, flammable processes. Safety compliance should have been a core, non-negotiable element during initial feasibility studies. If proper HAZOP (Hazard and Operability Study) and SIL (Safety Integrity Level) assessments had been conducted in 2023, why wait until construction drawings were finalized to discover “non-compliant layout”?

Even more troubling, Acore’s original feasibility report projected annual revenue of RMB 680 million and net profit of RMB 120 million post-commissioning, with an internal rate of return (IRR) exceeding 20%. These rosy forecasts assumed “high prices, strong demand, low competition”—grossly underestimating the risks of cyclical downturns and capacity glut. Now, with capacity halved and timelines extended, IRR will inevitably shrink, exposing a “pro-cyclical dependency syndrome”: bold only when tailwinds blow, lacking resilience when headwinds hit.

The table below compares key metrics before and after the project adjustment:

Notably, despite lower total investment, the cost per ton of capacity has surged by over 50%. This means even if the scaled-down plant operates smoothly, its fixed-cost burden will be significantly higher than originally planned—further squeezing margins. This isn’t “optimization”; it’s damage control through strategic retreat.

Raised Funds “Unmoved,” Own Capital “Amputated”: Are Shareholders Really Protected?

The announcement emphasizes: “The amount of raised funds used remains unchanged at RMB 2.07 billion; adjustments are achieved primarily by reducing the company’s own capital contribution.” This seems designed to reassure investors—“your money wasn’t wasted.” But read between the lines, and unease grows: Is the company preserving raised fund usage not out of economic logic, but regulatory necessity?

Under China’s Regulatory Guidelines No. 2 for Listed Companies, major changes to fundraising projects require shareholder approval. If Acore had outright terminated the project or drastically reduced raised fund allocation, it would face regulatory scrutiny or even investor lawsuits. Thus, keeping the RMB 2.07 billion expenditure intact is essentially a “technical compromise” within compliance boundaries. But this compromise comes at a steep cost: the project’s economic viability is fundamentally weakened—building a smaller, more expensive, later-to-market facility with the same pool of raised capital.

More ironically, as of October 31, 2025, RMB 1.57 billion (75.7%) of the raised funds had already been spent—mostly on civil works and equipment prepayments—leaving little room to pivot or reallocate. Acore is now trapped in its own “capital trap,” forced to complete this “downsized” plant even if future returns look bleak.

From “Chasing Tailwinds” to “Surviving Cycles”—The Coming-of-Age Trial for China’s Specialty Chemical Sector

Acore’s PEA predicament is far from unique. It reflects the collective growing pains of China’s specialty chemical industry after its rapid expansion phase: technological breakthroughs grant temporary leadership, but capital euphoria breeds capacity bubbles, which then burst in downturns, exposing fragile foundations. Companies that once rallied behind slogans like “import substitution” and “breaking chokepoint technologies” now face a harsh truth—overcoming foreign monopolies is just step one; surviving in an oversupplied market is the real test of endurance.

For Acore, the priority is no longer how much capacity it builds, but whether it can perfectly time the next demand recovery cycle when it finally commissions in 2026. If offshore wind projects accelerate or solid-state batteries drive new adhesive demand, its 10,000-ton line might find breathing room. But if the industry keeps cannibalizing itself, what awaits may not be another “adjustment,” but a full strategic pivot.

This retreat—from a “10,000-ton bet” to a “5,000-ton test”—may well be the necessary rite of passage for Chinese chemical firms to mature: true strength isn’t measured by how high you fly in good times, but how long you survive in the winter. Whether Acore endures this freeze will determine if it becomes the next Wanhua Chemical—or just another casualty swallowed by the cycle.